6:47pm

Icahn steps up Herbalife fight with Ackman

Activist investor lifts pressure by building a 13% stake

From HEALTH CARE 10:05pm

Cardinal in $2bn AssuraMed home care deal

Remote care increasingly important due to Obama incentives

Feb 14, 2013

Adult demand for ADD drug lifts Shire

Sales rise 12% despite generic competition

From TECHNOLOGY Feb 14, 2013

Fish threatened by exposure to tranquilliser

Swedish study raises alarm over ecological effects of medicines

Feb 12, 2013

FDA rejects Novo Nordisk insulin remedy

Shares in Danish drugmaker fall 13% after setback

Feb 11, 2013

e-Therapeutics plans to raise £40m

Biggest new investor is Aviva

Feb 11, 2013

Perrigo expands UK presence

£180m acquisition of Rosemont

From LEX Feb 11, 2013

Novo Nordisk: reality check

The specialist in diabetic treatments gets hit by an FDA ruling

From WORLD Feb 8, 2013

DNA testers latch on to scandal

Full tests cost £300 and can check for only one species

Feb 8, 2013

Sanofi forecasts possible earnings dip

Fourth-quarter core profits down 24%

From HEALTH CARE Feb 7, 2013

S&N solid finish outweighs weaker outlook

Good news on knee implants and wound management buoy Smith & Nephew

Feb 6, 2013

Biogen to buy Elan’s stake in MS drug

US biotechnology company to pay $3.25bn in cash for full control of Tysabri

Feb 6, 2013

GSK unveils European restructuring plans

Lucozade and Ribena drinks brands placed under review

From LEX Feb 6, 2013

Elan / Biogen: where are the drugs?

Biotech group needs a new strategy now more than ever

Feb 5, 2013

Campaigners welcome GSK disclosure move

Clinical study reports to be released

From TECHNOLOGY Feb 4, 2013

Needle-free syringe passes test on mice

Technique could improve distribution of fragile vaccines

From MANAGEMENT Feb 4, 2013

A new corporate focus

When Japanese pharma company Takeda tried to become more global, changing its internal culture started at the top

John Authers from FINANCIALS Feb 3, 2013

Activist spat distracts from real targets

All the signs suggest this is a great time to take aim at boards

Jan 31, 2013

AstraZeneca warns of tough year ahead

Focus at Anglo-Swedish drugmaker is on organic growth

Jan 31, 2013

Zoetis raises $2.24bn in IPO

Pfizer spin-off is largest listing since Facebook

MOST POPULAR NOW ON FT.COM

COMPANIES NEWS ON TWITTER

More FT Twitter accounts